Hemostasis and Thrombosis Flashcards
Thrombocytopenia
- low platelet count
- ID: petichial hemorrhage, ecchymosis, fever, nausea, vomiting, epistaxis, platelet count
- causes: medications that impair marrow function, peripheral destruction, decreased production, portal hypertension and splenomegaly
Thrombocytopenia- Heparin-induced (HIT)
- Heparin complexes with platelet factor 4 –> IgG Ab response –> FC binds to FCgiia activation of platelets –> thrombosis
- ID: PF4 ELISA, medium reduction in platelet count (usually no bleeding)
- Tx: stop heparin, provide lepirudin NOT warfarin b/c of warfarin necrosis
Warfarin necrosis
- warfarin blocks vitamin k –> inhibition of protein C, VII, II, IX, X–> protein C and VII have shorter half lives and are inhibited more strongly –> cant inhibit 5,8 –> coagulative state –> thrombosis –> gangrene
- Tx: stop warfarin, provide Vitamin K, provide heparin for first few days before starting warfarin, FFP/Protein C provision
Thrombocytopenia- Idiopathic/Immune/ITP
- IgG antibodies directed against platelet GP IIB/IIIA or Ib9 –> opsonophagocytosis by splenic macrophages –> Thrombocytopenia –> bleeding
- ID: no splenomegaly, bleeding, by exclusion
- Tx: corticosteroids or IVIg, splenectomy, immunosuppression, anti-D, TPO agonist
Thrombocytopenia-Thrombotic thrombocytopenic purpura/TTP
- disseminated microthrombi
- cause: deficiency or inhibition of ADAMTS13 –> accumulation of vWF multimers –> long strands snare platelets –> shear stress in microcirculation –> hemolysis
- ID: Pentad: fever, anemia (MAHA), thrombocytopenia, renal failure, neurologic symptoms
- ADAMTS13 >5% + shiga toxin = HUS
- ADAMTS13 >5% = aHUS
- ADAMTS13 <5% = TTP
- Tx: plasmapheresis, immunosuppressants
von Willebrand Disease
- poor platelet adhesion and decreased stabilization of factor VIII
- vWF produced in endothelium and stored in Palade bodies
- in absence of vWF –> Factor VIII degraded rapidly
- Type 1: low vWF of all sizes
- mostly asymptomatic/ epistaxis
- Type 2: qualitative functional defects–> lack high molecular weight multimers
- abnormal multimers
- Type 3: deficiency of vWF and Factor VIII –> profound hemorrhage
- ID: aPTT increased, NO muscle/joint bleeding
- quantity: vWF antigen assay
- function: ristocetin cofactor
- Factor VIII level
- function: gel electropheresis-multimer analysis
- Tx: DDAVP stimulates endogenous VWF release
aPTT
- evaluates intrinsic pathway
- longer w/deficiencies in 1, 5, 8, 9, 10, 11, 12
- long aPTT due to 12, PK, HMWK may not matter in vivo
- longer in hemophilia, von willebrand disease, DIC, antiphospholipid antibody, heparin, factor inhibitors
- Mixing test
- dissapear –> factor deficiency
- still prolonged –> factor inhibitor (heparin, antibody, factor specific)
PT
- measure of extrinsic/common pathway–>often reported as INR to standardize reagants
- prolonged by deficiency in 1, 2, 5, 7, 10
- also prolonged in warfarin, DIC, liver faiulre
Bleeding- Vitamin K
- Vitamin K needed for production of 2, 7, 9, 10, C, S –> lengthen PTT and PT if deficient
- warfarin necrosis due to relative half lives of C and 7 vs other factors lead to hypercoagulable state b/c of reduced inhibition of 5 and 8
Thrombin
- circulates as prothrombin
- -> cleaves to thrombin by X
- cleaves fibrinogen to fibrin
- activates platelets
- induces TF synthesis
- activates 5, 8, 9, 11
- binds to thrombomodulin to induce protein C negative feedback
- generated during
- inflammation
- infection
- hemostasis
- endothelial damage
- platelet activation
Antithrombin
- inactivates contact phase: 2, 9 10, 11, 12, kallikrein, plasmin
- activity increased by heparin –> inactivates 2, 10
Fibrinolysis
- cross-linked fibrin clots ensare proenzyme plasminogen –> converted to plasmin by plasminogen activator from endothelial cells –> lyses into d-dimers
- activation promoted by
- plasminogen activator
- thrombin
- urokinase
- Tx modality: recomb t-Pa used to promote fibrinolysis
- increases risk of secondary hemorrhage
*
- increases risk of secondary hemorrhage
D-dimers
- fibrinolysis split product
- indicative of
- DIC
- DVT
- PE
Coagulopathy-Hemophilia
- A: deficiency in 8
- B: deficiency in 9
- C: deficiency in 11
- Acquired A: auto-antibody = aPTT not resolved with mixing test
- ID: long PTT, bleeding, factor assay//mimicked by vW disease
Coagulopathy-Liver Disease
- liver produces 1, 2, 4, 5, 6, 7
- ID: extended PT
- causes: hepatitis, EBV, CMV, HSV, parvo, acetaminophen, methanol, isoniazid, chronic disease
Coagulopathy-Dilutional
reduction in platelets and clotting factors due to RBC transfusion without plasma replensihment
Coagulopathy-DIC
- cytokines, endotoxins–> release of TF–> microthrombtic condition that consumes coagulation proteins, inhibitors, and platelets –> paradoxical bleeding
- causes: cancer, preeclampsia, trauma, burns, infections, liver disease, snake bites, viral hemorrhagic fever
- ID: low platelets, low fibrinogen, prolonged PT, less prolonged PTT, positive D-dimer
Coagulopathy-Factor V Leiden
- hereditary thrombophilia that alters the inactivation site used by Protein C–> ongoing thrombin production –> DVT
- ID: aPTT with and without protein C
- Tx: prophylactic anticoagulation
Coagulopathy-Antithrombin deficiency
- prolonged circulation of activated factors –> thromboembolic events (especially mesentery)
- Type 1: reduced levels of normal AT
- Type 2: abnormal AT: thrombin binding site defects, heparin binding site defects,thrombin and heparain binding site defects
- ID:
- antigen assay-levels
- functional assay
- both reduced in type 1, function only in type 2
- heparin-resistant
Coagulopathy-Protein C deficiency
- associated with warfarin-induced skin necrosis and neonatal purpura fulminans
- converts to active form by thrombin when bound to thrombomodulin
- Type 1: reduced level
- Type 2: functionally abnormal
- ID:
- antigen assay
- functional assay
- both down in type 1
- functional down in type 2
Coagulopathy-Antiphospholipid Syndrome/Lupus anticoagulant
- antibodies to ß2 gp I and cardiolipin –> inhibition of Protein C, increased cleavage of prothrombin, etc. –> thrombosis
- ID: lupus anticoagulant assay, anti-cardiolipin ELISA
Tissue Factor
- initiating event in the hemostatic response to injury
- present in the vascular wall where it is expressed on the surface of vascular smooth muscle cells, activated monocytes and, in some disease states, endothelial cells composed of an apoprotein and phospholipid
- anchored to the cell membrane by a transmembrane domain and a short cytoplasmic domain.
Prothrombinase complex
5, 10, Calcium, phospholipids catalyze cleavage of prothrombin to thrombin
F1.2
small peptide thrown off during thrombin formation –> measure of thrombin formation